BridgeBio Pharma Announces Agreement with U.S. Government to Expand Medicine Access

BridgeBio Pharma Enters Voluntary Agreement with U.S. Government

On August 31, 2026, BridgeBio Pharma, Inc. filed a Form 8-K under Item 8.01 (Other Events) announcing a voluntary agreement with the U.S. government aimed at improving affordability and expanding patient access to critical medicines for rare genetic conditions.

Key Event Details:

• Medicaid Expansion: BridgeBio will expand state Medicaid access to its commercial medicine, Attruby™ (acoramidis), through the GENEROUS Model.
• Orphan Drug Exclusions: The company expects its pricing commitments under the agreement to exclude medicines approved exclusively for orphan indications.
• Pricing Mandates: BridgeBio indicated it does not expect to be subject to future pricing mandates, and the agreement preserves its ForgingBridges® copay assistance program.
• Signatories & Leadership: The report was signed by President and Chief Financial Officer Thomas Trimarchi, following discussions between CEO Neil Kumar, Ph.D., and the Administration.